This study examined a gene therapy called rAAV2.REP1 in people with vision loss due to choroideremia, an inherited eye disease. It enrolled male patients over 18 who had a certain level of vision in the study eye. It was carried out in Phase 1/Phase 2 and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Participant is willing and able to give informed consent for participation in the study, * Male aged 18 years or above, * Diagnosed with choroideraemia and in good health, * Active disease with SLO changes visible within the macula region, * Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the study, * Vision at least 6/60 or better in the study eye. Exclusion Criteria: * Female and child participants (under the age of 18), * Men unwilling to use barrier contraception methods, if relevant, * Previous history of retinal surgery or ocular inflammatory disease (uveitis), * Grossly asymmetrical disease or other ocular morbidity which might confound use of the fellow eye as a long-term control, * Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study, * Participants who have participated in another research study involving an investigational product in the previous 12 weeks.